Chemokine's anticancer drug shrinks tumor during preclinical study

By Angela McDaniels

Seattle, Feb. 23 - Chemokine Therapeutics Corp. said its CTCE-9908 anticancer compound prevented the spread of established human prostate cancer to distant organs in preclinical models by an average of 61%.

This reduction was apparent with both subcutaneous and intraperitoneal administration of the drug, the company said.

Chemokine will present the data on April 3 at the 97th Annual Meeting of the American Association for Cancer Research in Washington, D.C.

The company said it has also completed a dose-escalation phase 1 clinical trial of the drug in healthy volunteers, which showed CTCE-9908 to be safe and well tolerated by the study subjects.

Health Canada granted approval for the company to begin a phase 1b/2 clinical trial of CTCE-9908, and Chemokine said it will begin the trial soon in up to 30 patients with late-stage cancers such as ovarian, lung and breast.

CTCE-9908 is designed to block the CXCR4 receptor, which has been identified as critical in the process of tumor metastasis to other tissues in the body, the company said. The CXCR4 receptor is present on most human tumors cells, including lung, breast, prostate, colon, ovarian, bone, brain and skin cancer.

Chemokine Therapeutics is a biotechnology company based in Vancouver, B.C., that develops chemokine-based therapies to treat cancer, blood disorders, cardiovascular disease and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.